NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014

Timothy Henry, MD, of Cedars-Sinai Heart Institute, to Review Clinical Data From Phase 2 PreSERVE AMI TrialNEW YORK, Nov 26, 2014 (GLOBE NEWSWIRE via COMTEX) NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 to 5:30 PM EST. The webcast will feature a presentation by Timothy Henry, MD, Director of Cardiology at the Cedars-Sinai Heart Institute, who will discuss the significance of the Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial, the results of which were previously announced on November 17. (http://www.neostem.com/media/press-releases/news-item/initial-preserve-data/) Dr. Henry is an internationally recognized expert in the treatment of patients with refractory angina and acute myocardial infarction, with a focus on stem cell therapies. Before joining Cedars-Sinai, Dr. Henry was the Director of Research at th
http://bit.ly/1uWi5zF